Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > ICO Partner Immune Trading at 1.1 Cent!!!

<< Previous

Bullboard Posts

Next >>

Comment by regardlesson Dec 21, 2018 12:39am

75 Views

Post# 29144649

RE:RE:RE:ICO Partner Immune Trading at 1.1 Cent!!!

Frankly I see ico making a bad deal to get any cash that it can to stay alive
you don’t get good deals when your low on cash

tell me when has there ever been a great deal for a company that has no revenue and hardly any cash

i hate to say it but without solid financial backing this company will
trade lower

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing